Biodexa Pharmaceuticals reports Preliminary FY results

seekingalpha04-20

Biodexa Pharmaceuticals press release (NASDAQ:BDRX): FY Biodexa generated consolidated total gross revenue of £0.38m Net cash outflow from operating activities in 2023 was £6.83m (2022: outflow £7.05...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428694535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-20 05:23","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2428694535","market":"sg","top_or_hot":-1,"title":"Biodexa Pharmaceuticals reports Preliminary FY results","media":"seekingalpha","content":"<div>\n<p>Biodexa Pharmaceuticals press release  (NASDAQ:BDRX): FY Biodexa generated consolidated total gross revenue of £0.38m\nNet cash outflow from operating activities in 2023 was £6.83m (2022: outflow £7.05...</p>\n\n<a href=\"https://seekingalpha.com/news/4091679-biodexa-pharmaceuticals-reports-preliminary-fy-results\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biodexa Pharmaceuticals reports Preliminary FY results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiodexa Pharmaceuticals reports Preliminary FY results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-20 05:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4091679-biodexa-pharmaceuticals-reports-preliminary-fy-results><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biodexa Pharmaceuticals press release  (NASDAQ:BDRX): FY Biodexa generated consolidated total gross revenue of £0.38m\nNet cash outflow from operating activities in 2023 was £6.83m (2022: outflow £7.05...</p>\n\n<a href=\"https://seekingalpha.com/news/4091679-biodexa-pharmaceuticals-reports-preliminary-fy-results\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BDRX","symbol_name":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD","start_time":0,"source_url":"https://seekingalpha.com/news/4091679-biodexa-pharmaceuticals-reports-preliminary-fy-results","article_id":"2428694535","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428694535","pubTimestamp":1713561797,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Biodexa Pharmaceuticals press release  : FYBiodexa generated consolidated total gross revenue of 0.38m. Net cash outflow from operating activities in 2023 was 6.83m  driven by a net loss of 7.08  and after negative movements in working capital of 0.05m. More on Biodexa Pharmaceuticals  Biodexa stock slides 7% amid data for two drug studies Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BDRX":"BIODEXA PHARMACEUTICALS PLC SPON ADS EACH REP 5 ORD","BK4139":"生物科技"},"translate_title":"Biodexa Pharmaceuticals公布财政年度初步业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDRX":1},"content_text":"Biodexa Pharmaceuticals press release  (NASDAQ:BDRX): FY Biodexa generated consolidated total gross revenue of £0.38m\nNet cash outflow from operating activities in 2023 was £6.83m (2022: outflow £7.05m) driven by a net loss of £7.08 (2022: loss £7.66m) and after negative movements in working capital of £0.05m \n\n\n\n\nMore on Biodexa Pharmaceuticals  Biodexa stock slides 7% amid data for two drug studies Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals Historical earnings data for Biodexa Pharmaceuticals Financial information for Biodexa Pharmaceuticals","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428694535"}